Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Efficacy and safety of molecularly targeted agents and immune checkpoint inhibitors for unresectable or recurrent/metastatic oral cancer in Japan

Background/purpose: For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Mitsunobu Otsuru, Nobuhiro Yamakawa, Tadaaki Kirita, Shin-ichi Yamada, Hiroshi Kurita, Takuma Kugimoto, Hiroyuki Harada, Takumi Hasegawa, Masaya Akashi, Akinori Takeshita, Narikazu Uzawa, Masahiro Umeda, Souichi Yanamoto, Tomohiro Yamada
Materialtyp: Artikel
Språk:English
Publicerad: Elsevier 2024-07-01
Serie:Journal of Dental Sciences
Ämnen:
Oral cancer
Immune checkpoint inhibitors (ICIs)
Progression-free survival (PFS)
PFS 2 (PFS2)
Japan
Länkar:http://www.sciencedirect.com/science/article/pii/S1991790223003914

Liknande verk

Liknande verk